John C Lieske

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2491782/publications.pdf

Version: 2024-02-01

245 papers

10,792 citations

28190 55 h-index 91 g-index

253 all docs

253 docs citations

times ranked

253

9404 citing authors

#	Article	IF	CITATIONS
1	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 36-46.	13.9	324
2	Current Issues in Measurement and Reporting of Urinary Albumin Excretion. Clinical Chemistry, 2009, 55, 24-38.	1.5	298
3	Kidney Stones and the Risk for Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 804-811.	2.2	296
4	Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney International, 2013, 83, 749-756.	2.6	268
5	Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. New England Journal of Medicine, 2021, 384, 1216-1226.	13.9	265
6	Temporal Trends in Incidence of Kidney Stones Among Children: A 25-Year Population Based Study. Journal of Urology, 2012, 188, 247-252.	0.2	260
7	Single-Nephron Glomerular Filtration Rate in Healthy Adults. New England Journal of Medicine, 2017, 376, 2349-2357.	13.9	247
8	Hereditary causes of kidney stones and chronic kidney disease. Pediatric Nephrology, 2013, 28, 1923-1942.	0.9	213
9	Stone Composition as a Function of Age and Sex. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 2141-2146.	2.2	200
10	Kidney Stones Associate with Increased Risk for Myocardial Infarction. Journal of the American Society of Nephrology: JASN, 2010, 21, 1641-1644.	3.0	191
11	The ROKS Nomogram for Predicting a Second Symptomatic Stone Episode. Journal of the American Society of Nephrology: JASN, 2014, 25, 2878-2886.	3.0	190
12	Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. Journal of the American Society of Nephrology: JASN, 2015, 26, 2559-2570.	3.0	185
13	Evaluating Muscle Mass by Using Markers of Kidney Function: Development of the Sarcopenia Index. Critical Care Medicine, 2017, 45, e23-e29.	0.4	179
14	Chronic Kidney Disease in Kidney Stone Formers. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2069-2075.	2.2	163
15	Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases, 2005, 1, 481-485.	1.0	157
16	Fat malabsorption and increased intestinal oxalate absorption are common after roux-en-Y gastric bypass surgery. Surgery, 2011, 149, 654-661.	1.0	152
17	Use of a probioitic to decrease enteric hyperoxaluria. Kidney International, 2005, 68, 1244-1249.	2.6	151
18	Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H1115-H1124.	1.5	142

#	Article	IF	Citations
19	Relative Performance of the MDRD and CKD-EPI Equations for Estimating Glomerular Filtration Rate among Patients with Varied Clinical Presentations. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1963-1972.	2.2	142
20	International Registry for Primary Hyperoxaluria. American Journal of Nephrology, 2005, 25, 290-296.	1.4	133
21	Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney International, 2010, 78, 1178-1185.	2.6	128
22	Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptorÂantibodies. Kidney International, 2019, 95, 429-438.	2.6	123
23	Diabetes Mellitus and the Risk of Urinary Tract Stones: A Population-Based Case-Control Study. American Journal of Kidney Diseases, 2006, 48, 897-904.	2.1	122
24	Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. Journal of Nephrology, 2016, 29, 715-734.	0.9	122
25	Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. Kidney International, 2013, 83, 1169-1176.	2.6	119
26	Adhesion, internalization and metabolism of calcium oxalate monohydrate crystals by renal epithelial cells. Kidney International, 1997, 52, 1291-1301.	2.6	109
27	DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney International Reports, 2018, 3, 56-64.	0.4	109
28	The Changing Incidence and Presentation of Urinary Stones Over 3 Decades. Mayo Clinic Proceedings, 2018, 93, 291-299.	1.4	107
29	Kidney stones are common after bariatric surgery. Kidney International, 2015, 87, 839-845.	2.6	106
30	Performance of Creatinine-Based GFR Estimating Equations inÂSolid-Organ Transplant Recipients. American Journal of Kidney Diseases, 2014, 63, 1007-1018.	2.1	103
31	Endocytosis of Calcium Oxalate Crystals and Proliferation of Renal Tubular Epithelial Cells in a Patient with Type 1 Primary Hyperoxaluria. Journal of Urology, 1992, 148, 1517-1519.	0.2	98
32	Stone Composition Among First-Time Symptomatic Kidney Stone Formers in the Community. Mayo Clinic Proceedings, 2015, 90, 1356-1365.	1.4	93
33	Risk Factors for CKD in Persons With Kidney Stones: A Case-Control Study in Olmsted County, Minnesota. American Journal of Kidney Diseases, 2010, 55, 61-68.	2.1	92
34	Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. Kidney International, 1995, 48, 501-509.	2.6	91
35	Distinguishing age-related from disease-related glomerulosclerosis on kidney biopsy: the Aging Kidney Anatomy study. Nephrology Dialysis Transplantation, 2015, 30, 2034-2039.	0.4	90
36	Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis. Journal of Nephrology, 2016, 29, 211-219.	0.9	86

#	Article	IF	Citations
37	Risk of Acute Kidney Injury, Dialysis, and Mortality in Patients With Chronic Kidney Disease After Intravenous Contrast Material Exposure. Mayo Clinic Proceedings, 2015, 90, 1046-1053.	1.4	81
38	Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 119-126.	2.2	81
39	Detection and Clinical Patterns of Nephron Hypertrophy and Nephrosclerosis Among Apparently Healthy Adults. American Journal of Kidney Diseases, 2016, 68, 58-67.	2.1	78
40	Association of Urinary Oxalate Excretion With the Risk of Chronic Kidney Disease Progression. JAMA Internal Medicine, 2019, 179, 542.	2.6	78
41	Update on Oxalate Crystal Disease. Current Rheumatology Reports, 2013, 15, 340.	2.1	74
42	Risk of ESRD and Mortality in Kidney and Bladder Stone Formers. American Journal of Kidney Diseases, 2018, 72, 790-797.	2.1	72
43	Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is more sensitive for early detection of acute kidney injury. Nephrology Dialysis Transplantation, 2013, 28, 1175-1185.	0.4	71
44	Predictors of Symptomatic Kidney Stone Recurrence After the First and Subsequent Episodes. Mayo Clinic Proceedings, 2019, 94, 202-210.	1.4	70
45	National Kidney Foundation Laboratory Engagement Working Group Recommendations for Implementing the CKD-EPI 2021 Race-Free Equations for Estimated Glomerular Filtration Rate: Practical Guidance for Clinical Laboratories. Clinical Chemistry, 2022, 68, 511-520.	1.5	70
46	Cell Biology of Pathologic Renal Calcification. Journal of Investigative Medicine, 2006, 54, 412-424.	0.7	66
47	Quantification of Urinary Albumin by Using Protein Cleavage and LC-MS/MS. Clinical Chemistry, 2009, 55, 1100-1107.	1.5	66
48	Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney International, 2015, 87, 623-631.	2.6	63
49	Pathophysiology and Treatment of Enteric Hyperoxaluria. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 487-495.	2.2	63
50	Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. Kidney International, 2013, 84, 818-825.	2.6	62
51	Rhus verniciflua Stokes prevents cisplatin-induced cytotoxicity and reactive oxygen species production in MDCK-I renal cells and intact mice. Phytomedicine, 2009, 16, 188-197.	2.3	61
52	Cardiac Abnormalities in Primary Hyperoxaluria. Circulation Journal, 2010, 74, 2403-2409.	0.7	61
53	Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study. Critical Care, 2014, 18, R110.	2.5	60
54	Cystatin C–Guided Vancomycin Dosing in Critically Ill Patients: AÂQuality Improvement Project. American Journal of Kidney Diseases, 2017, 69, 658-666.	2.1	60

#	Article	lF	CITATIONS
55	No increase in the incidence of acute kidney injuryÂin a population-based annual temporalÂtrends epidemiology study. Kidney International, 2017, 92, 721-728.	2.6	57
56	The genetics of kidney stone disease and nephrocalcinosis. Nature Reviews Nephrology, 2022, 18, 224-240.	4.1	57
57	Effect of Age on the Clinical Presentation of Incident Symptomatic Urolithiasis in the General Population. Journal of Urology, 2013, 189, 158-164.	0.2	56
58	State of the Art for Measurement of Urine Albumin: Comparison of Routine Measurement Procedures to Isotope Dilution Tandem Mass Spectrometry. Clinical Chemistry, 2014, 60, 471-480.	1.5	55
59	Specific renal parenchymalâ€derived urinary extracellular vesicles identify ageâ€associated structural changes in living donor kidneys. Journal of Extracellular Vesicles, 2016, 5, 29642.	5.5	55
60	Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. Kidney International, 2005, 68, 1784-1792.	2.6	54
61	Nephrolithiasis After Bariatric Surgery for Obesity. Seminars in Nephrology, 2008, 28, 163-173.	0.6	54
62	Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events. Kidney International Reports, 2021, 6, 1022-1031.	0.4	54
63	Complete Remission in the Nephrotic Syndrome Study Network. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 81-89.	2.2	53
64	Discordance Between Iothalamate and Iohexol UrinaryÂClearances. American Journal of Kidney Diseases, 2016, 67, 49-55.	2.1	52
65	Direct nucleation of calcium oxalate dihydrate crystals onto the surface of living renal epithelial cells in culture. Kidney International, 1998, 54, 796-803.	2.6	51
66	Shock Wave Lithotripsy is Not Predictive of Hypertension Among Community Stone Formers at Long-Term Followup. Journal of Urology, 2011, 185, 164-169.	0.2	51
67	The relatively poor correlation between random andÂ24-hour urine protein excretion in patients withÂbiopsy-proven glomerular diseases. Kidney International, 2016, 90, 1080-1089.	2.6	51
68	End Points for Clinical Trials in Primary Hyperoxaluria. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1056-1065.	2.2	51
69	Whole Urinary Proteins Coat Calcium Oxalate Monohydrate Crystals to Greatly Decrease Their Adhesion to Renal Cells. Journal of Urology, 2003, 170, 221-225.	0.2	50
70	Geobiology reveals how human kidney stones dissolve in vivo. Scientific Reports, 2018, 8, 13731.	1.6	50
71	Clinical Impact of the Refit CKD-EPI 2021 Creatinine-Based eGFR Equation. Clinical Chemistry, 2022, 68, 534-539.	1.5	49
72	Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1025-1036.	2.2	48

#	Article	IF	CITATIONS
73	Sialic acid-containing glycoproteins on renal cells determine nucleation of calcium oxalate dihydrate crystals. Kidney International, 2001, 60, 1784-1791.	2.6	47
74	A Liquid Chromatography-Mass Spectrometry Method for the Quantification of Urinary Albumin using a Novel 15N-Isotopically Labeled Albumin Internal Standard. Clinical Chemistry, 2007, 53, 540-542.	1.5	47
75	Glomerular Pathology in Dent Disease and Its Association with Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2168-2176.	2.2	47
76	A Target Antigen–Based Approach to the Classification of Membranous Nephropathy. Mayo Clinic Proceedings, 2021, 96, 577-591.	1.4	45
77	Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria. ELife, 2020, 9, .	2.8	45
78	Performance of Cystatin C– and Creatinine-Based Estimated Glomerular Filtration Rate Equations Depends on Patient Characteristics. Clinical Chemistry, 2015, 61, 1265-1272.	1.5	44
79	Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. Clinical Biochemistry, 2017, 50, 1014-1019.	0.8	44
80	Genome-wide meta-analysis of macronutrient intake of 91,114 European ancestry participants from the cohorts for heart and aging research in genomic epidemiology consortium. Molecular Psychiatry, 2019, 24, 1920-1932.	4.1	44
81	Management of Kidney Stones in 2020. JAMA - Journal of the American Medical Association, 2020, 323, 1961.	3.8	44
82	EXTRACT FROM HERNIARIA HIRSUTA COATS CALCIUM OXALATE MONOHYDRATE CRYSTALS AND BLOCKS THEIR ADHESION TO RENAL EPITHELIAL CELLS. Journal of Urology, 2004, 172, 1510-1514.	0.2	42
83	Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review. Mayo Clinic Proceedings, 2019, 94, 500-514.	1.4	42
84	Quantification of Asymptomatic Kidney Stone Burden by Computed Tomography for Predicting Future Symptomatic Stone Events. Urology, 2015, 85, 45-50.	0.5	41
85	Probiotics for prevention of urinary stones. Annals of Translational Medicine, 2017, 5, 29-29.	0.7	41
86	Search for Microbial Signatures within Human and Microbial Calcifications Using Soft X-Ray Spectromicroscopy. Journal of Investigative Medicine, 2006, 54, 367-379.	0.7	40
87	Sensitive Spectrophotometric Assay for Plasma Oxalate. Clinical Chemistry, 2005, 51, 2377-2380.	1.5	39
88	Glomerular Volume and Glomerulosclerosis at Different Depths within the Human Kidney. Journal of the American Society of Nephrology: JASN, 2019, 30, 1471-1480.	3.0	39
89	1,2,3,4,6-Penta-O-galloyl-beta-D-glucose reduces renal crystallization and oxidative stress in a hyperoxaluric rat model. Kidney International, 2011, 79, 538-545.	2.6	37
90	Extracellular vesicles in urine of women with but not without kidney stones manifest patterns similar to men: a case control study. Biology of Sex Differences, 2015, 6, 2.	1.8	37

#	Article	IF	Citations
91	Distinguishing Characteristics of Idiopathic Calcium Oxalate Kidney Stone Formers with Low Amounts of Randall's Plaque. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1757-1763.	2.2	36
92	Gastric Bypass Surgery and Measured and Estimated GFR in Women. American Journal of Kidney Diseases, 2014, 64, 663-665.	2.1	35
93	Modulation of Proliferating Renal Epithelial Cell Affinity for Calcium Oxalate Monohydrate Crystals. Journal of the American Society of Nephrology: JASN, 2004, 15, 3052-3062.	3.0	33
94	Performance of flow cytometry to screen urine for bacteria and white blood cells prior to urine culture. Clinical Biochemistry, 2013, 46, 810-813.	0.8	33
95	A reference system for urinary albumin: current status. Clinical Chemistry and Laboratory Medicine, 2013, 51, 981-9.	1.4	33
96	Creatinine–Based and Cystatin C–Based GFR Estimating Equations and Their Non-GFR Determinants in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1640-1649.	2.2	33
97	Clinical and Pathology Findings Associate Consistently with Larger Glomerular Volume. Journal of the American Society of Nephrology: JASN, 2018, 29, 1960-1969.	3.0	33
98	Altered Calcium and Vitamin D Homeostasis in First-Time Calcium Kidney Stone-Formers. PLoS ONE, 2015, 10, e0137350.	1.1	31
99	Heritability of Urinary Traits That Contribute to Nephrolithiasis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 943-950.	2.2	30
100	Cystatin C Predicts Renal Recovery Earlier Than Creatinine Among Patients With Acute Kidney Injury. Kidney International Reports, 2018, 3, 337-342.	0.4	30
101	Larger Nephron Size and Nephrosclerosis Predict Progressive CKD and Mortality after Radical Nephrectomy for Tumor and Independent of Kidney Function. Journal of the American Society of Nephrology: JASN, 2020, 31, 2642-2652.	3.0	30
102	Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children. Genetics in Medicine, 2022, 24, 654-662.	1.1	30
103	Controlled Metabolic Diet Reduces Calcium Oxalate Supersaturation but Not Oxalate Excretion After Bariatric Surgery. Urology, 2012, 80, 250-254.	0.5	29
104	Analytical performance of an immunoassay to measure proenkephalin. Clinical Biochemistry, 2018, 58, 72-77.	0.8	28
105	Tamm-Horsfall protein/uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia. American Journal of Physiology - Renal Physiology, 2018, 314, F1062-F1076.	1.3	28
106	Understanding, justifying, and optimizing radiation exposure for CT imaging in nephrourology. Nature Reviews Urology, 2019, 16, 231-244.	1.9	28
107	Use of Sevelamer Hydrochloride as an Oxalate Binder. Journal of Urology, 2008, 179, 1407-1410.	0.2	27
108	Human kidney stones: a natural record of universal biomineralization. Nature Reviews Urology, 2021, 18, 404-432.	1.9	27

#	Article	IF	Citations
109	Human-derived nanoparticles and vascular response to injury in rabbit carotid arteries: Proof of principle. International Journal of Nanomedicine, 2008, 3, 243.	3.3	26
110	Importance of Cystatin C Assay Standardization. Clinical Chemistry, 2011, 57, 1209-1211.	1.5	26
111	Serum levels of DNAJB9 are elevated in fibrillaryÂglomerulonephritis patients. Kidney International, 2019, 95, 1269-1272.	2.6	26
112	Tubular secretion of creatinine and kidney function: an observational study. BMC Nephrology, 2020, 21, 108.	0.8	26
113	Analytic and clinical validation of a standardized cystatin C particle enhanced turbidimetric assay (PETIA) to estimate glomerular filtration rate. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1591-6.	1.4	24
114	Challenges in Measuring Glomerular Filtration Rate: A Clinical Laboratory Perspective. Advances in Chronic Kidney Disease, 2018, 25, 84-92.	0.6	24
115	Iothalamate Quantification by Tandem Mass Spectrometry to Measure Glomerular Filtration Rate. Clinical Chemistry, 2010, 56, 568-574.	1.5	23
116	Urinalysis for the diagnosis of glomerulonephritis: role of dysmorphic red blood cells. Nephrology Dialysis Transplantation, 2018, 33, 1397-1403.	0.4	23
117	Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2. Nephrology Dialysis Transplantation, 2022, 37, 869-875.	0.4	23
118	Proteomic evaluation of biological nanoparticles isolated from human kidney stones and calcified arteries. Acta Biomaterialia, 2010, 6, 4065-4072.	4.1	22
119	Oxalate Quantification in Hemodialysate to Assess Dialysis Adequacy for Primary Hyperoxaluria. American Journal of Nephrology, 2014, 39, 376-382.	1.4	22
120	Secondarily Infected Nonstruvite Urolithiasis: A Prospective Evaluation. Urology, 2014, 84, 1295-1300.	0.5	21
121	Calcifying nanoparticles promote mineralization in vascular smooth muscle cells: implications for atherosclerosis. International Journal of Nanomedicine, 2014, 9, 2689.	3.3	21
122	Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. American Journal of Kidney Diseases, 2023, 81, 145-155.e1.	2.1	21
123	The effect of ions at the surface of calcium oxalate monohydrate crystals on cell-crystal interactions. Urological Research, 2004, 32, 117-123.	1.5	20
124	Dent disease: A window into calcium and phosphate transport. Journal of Cellular and Molecular Medicine, 2019, 23, 7132-7142.	1.6	20
125	Pyridoxine Responsiveness in a Type 1 Primary Hyperoxaluria Patient With a Rare (Atypical) AGXT Gene Mutation. Kidney International Reports, 2020, 5, 955-958.	0.4	20
126	Plasma Oxalate as a Predictor of Kidney Function Decline in a Primary Hyperoxaluria Cohort. International Journal of Molecular Sciences, 2020, 21, 3608.	1.8	20

#	Article	IF	CITATIONS
127	Renal cell adaptation to oxalate. Urological Research, 2005, 33, 340-348.	1.5	19
128	Key influence of sex on urine volume and osmolality. Biology of Sex Differences, 2016, 7, 12.	1.8	19
129	GeoBioMed sheds new light on human kidney stone crystallization and dissolution. Nature Reviews Urology, 2020, 17, 1-2.	1.9	19
130	Measurement of urinary TGF- \hat{l}^21 in patients with diabetes mellitus and normal controls. Clinical Biochemistry, 2013, 46, 1430-1435.	0.8	18
131	Endoscopic and Histologic Findings in a Cohort of Uric Acid and Calcium Oxalate Stone Formers. Urology, 2015, 85, 771-776.	0.5	18
132	Kidney Function After the First Kidney Stone Event. Mayo Clinic Proceedings, 2016, 91, 1744-1752.	1.4	18
133	The Synthesized Plant Metabolite 3,4,5-Tri- <i>O</i> Galloylquinic Acid Methyl Ester Inhibits Calcium Oxalate Crystal Growth in a <i>Drosophila</i> Model, Downregulates Renal Cell Surface Annexin A1 Expression, and Decreases Crystal Adhesion to Cells. Journal of Medicinal Chemistry, 2018, 61, 1609-1621.	2.9	18
134	Characterization of biofilm formed by human-derived nanoparticles. Nanomedicine, 2009, 4, 931-941.	1.7	17
135	Systemic injection of planktonic forms of mammalian-derived nanoparticles alters arterial response to injury in rabbits. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H1434-H1441.	1.5	17
136	1,2,3,4,6-penta-O-galloyl-beta-d-glucose attenuates renal cell migration, hyaluronan expression, and crystal adhesion. European Journal of Pharmacology, 2009, 606, 32-37.	1.7	17
137	Effect of Demographics on Excretion of Key Urinary Factors Related to Kidney Stone Risk. Urology, 2015, 86, 690-696.	0.5	17
138	Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations. Journal of Urology, 2016, 195, 1476-1481.	0.2	17
139	Key role of alkaline phosphatase in the development of human-derived nanoparticles in vitro. Acta Biomaterialia, 2011, 7, 1339-1345.	4.1	16
140	Urinary extracellular vesicle-associated MCP-1 and NGAL derived from specific nephron segments differ between calcium oxalate stone formers and controls. American Journal of Physiology - Renal Physiology, 2019, 317, F1475-F1482.	1.3	16
141	Plasma oxalate: comparison of methodologies. Urolithiasis, 2020, 48, 473-480.	1.2	16
142	SLC2A9 Genotype Is Associated with SLC2A9 Gene Expression and Urinary Uric Acid Concentration. PLoS ONE, 2015, 10, e0128593.	1.1	16
143	Cystone \hat{A}^{\otimes} for $1\hat{A}$ year did not change urine chemistry or decrease stone burden in cystine stone formers. Urological Research, 2011, 39, 197-203.	1.5	15
144	New Insights Regarding the Interrelationship of Obesity, Diet, Physical Activity, and Kidney Stones. Journal of the American Society of Nephrology: JASN, 2014, 25, 211-212.	3.0	15

#	Article	IF	CITATIONS
145	Specific populations of urinary extracellular vesicles and proteins differentiate type 1 primary hyperoxaluria patients without and with nephrocalcinosis or kidney stones. Orphanet Journal of Rare Diseases, 2020, 15, 319.	1.2	15
146	Risk of Symptomatic Kidney Stones During and After Pregnancy. American Journal of Kidney Diseases, 2021, 78, 409-417.	2.1	15
147	Comprehensive Genetic Analysis Reveals Complexity of Monogenic Urinary Stone Disease. Kidney International Reports, 2021, 6, 2862-2884.	0.4	15
148	Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1. Kidney International Reports, 2022, 7, 494-506.	0.4	15
149	Thiazide Diuretic Prophylaxis for Kidney Stones and the Risk of Diabetes Mellitus. Journal of Urology, 2014, 192, 1700-1704.	0.2	14
150	Strategy and rationale for urine collection protocols employed in the NEPTUNE study. BMC Nephrology, 2015, 16, 190.	0.8	14
151	Association between kidney intracapsular pressure and ultrasound elastography. Critical Care, 2017, 21, 251.	2.5	14
152	Point mutation in D8C domain of Tamm-Horsfall protein/uromodulin in transgenic mice causes progressive renal damage and hyperuricemia. PLoS ONE, 2017, 12, e0186769.	1.1	14
153	Comparison of high glomerular filtration rate thresholds for identifying hyperfiltration. Nephrology Dialysis Transplantation, 2020, 35, 1017-1026.	0.4	14
154	Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts. Pediatric Nephrology, 2020, 35, 633-640.	0.9	14
155	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.	1.4	14
156	Establishing a nephrology genetic clinic. Kidney International, 2021, 100, 254-259.	2.6	14
157	In Vivo Entombment of Bacteria and Fungi during Calcium Oxalate, Brushite, and Struvite Urolithiasis. Kidney360, 2021, 2, 298-311.	0.9	14
158	Sulfate but Not Thiosulfate Reduces Calculated and Measured Urinary Ionized Calcium and Supersaturation: Implications for the Treatment of Calcium Renal Stones. PLoS ONE, 2014, 9, e103602.	1.1	13
159	Functional and transport analyses of <i>CLCN5</i> genetic changes identified in Dent disease patients. Physiological Reports, 2016, 4, e12776.	0.7	13
160	Heritability of dietary traits that contribute to nephrolithiasis in a cohort of adult sibships. Journal of Nephrology, 2016, 29, 45-51.	0.9	13
161	Standardization of Urine Albumin Measurements: Status and Performance Goals. journal of applied laboratory medicine, The, 2017, 2, 423-429.	0.6	13
162	Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening. Kidney International, 2020, 97, 786-792.	2.6	13

#	Article	IF	Citations
163	Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity. Kidney International Reports, 2020, 5, 2021-2031.	0.4	13
164	Excretion of urine extracellular vesicles bearing markers of activated immune cells and calcium/phosphorus physiology differ between calcium kidney stone formers and non-stone formers. BMC Nephrology, 2021, 22, 204.	0.8	13
165	Genomics Integration Into Nephrology Practice. Kidney Medicine, 2021, 3, 785-798.	1.0	13
166	Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia. Nephrology Dialysis Transplantation, 2021, 36, 945-948.	0.4	13
167	Aqueous extract of Costus arabicus inhibits calcium oxalate crystal growth and adhesion to renal epithelial cells. Urolithiasis, 2015, 43, 119-124.	1.2	12
168	Longitudinal characterization of renal proximal tubular markers in normotensive and preeclamptic pregnancies. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017, 312, R773-R778.	0.9	12
169	Impact of Serum Cystatin C–Based Glomerular Filtration Rate Estimates on Drug Dose Selection in Hospitalized Patients. Pharmacotherapy, 2018, 38, 1068-1073.	1.2	12
170	Oxalosis Associated With High-Dose Vitamin C Ingestion in a Peritoneal Dialysis Patient. American Journal of Kidney Diseases, 2019, 74, 417-420.	2.1	12
171	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	2.8	12
172	Risk Factors for Acute Kidney Injury in Hospitalized Non–Critically III Patients: AÂPopulation-Based Study. Mayo Clinic Proceedings, 2020, 95, 459-467.	1.4	12
173	Can biologic nanoparticles initiate nephrolithiasis?. Nature Clinical Practice Nephrology, 2008, 4, 308-309.	2.0	11
174	The Influence of Processing and Storage Conditions on Renal Protein Biomarkers. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1726-1728.	2.2	11
175	Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases. American Journal of Kidney Diseases, 2021, 77, 816-819.	2.1	11
176	Tubulointerstitial Fibrosis of Living Donor Kidneys Associates with Urinary Monocyte Chemoattractant Protein 1. American Journal of Nephrology, 2016, 43, 454-459.	1.4	10
177	Heritable traits that contribute to nephrolithiasis. Urolithiasis, 2019, 47, 5-10.	1.2	10
178	Patterns of Cystatin C Uptake and Use Across and Within Hospitals. Mayo Clinic Proceedings, 2020, 95, 1649-1659.	1.4	10
179	Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report. American Journal of Kidney Diseases, 2022, 79, 125-128.	2.1	10
180	Primary hyperoxaluria type 1: novel therapies at a glance. CKJ: Clinical Kidney Journal, 2022, 15, i17-i22.	1.4	10

#	Article	IF	CITATIONS
181	Endoscopic and Pathologic Characterization of Papillary Architecture in Struvite Stone Formers. Urology, 2016, 90, 39-44.	0.5	9
182	Overestimation of Glomerular Filtration Rate Among Critically Ill Adults With Hospital-Acquired Oligoanuric Acute Kidney Injury. Journal of Pharmacy Practice, 2016, 29, 125-131.	0.5	9
183	Treatment of Cholesterol Embolization Syndrome in the Setting of an Acute Indication for Anticoagulation Therapy. Journal of Medical Cases, 2014, 5, 376-379.	0.4	9
184	Estimating Glomerular Filtration Rate from Serum Myo-Inositol, Valine, Creatinine and Cystatin C. Diagnostics, 2021, 11, 2291.	1.3	9
185	Looking for a Better Creatinine. Clinical Chemistry, 2014, 60, 1036-1039.	1.5	8
186	Digenic mutations of human OCRL paralogs in Dent's disease type 2 associated with Chiari I malformation. Human Genome Variation, 2016, 3, 16042.	0.4	8
187	Polymorphisms in Renal Ammonia Metabolism Genes Correlate With 24-Hour Urine pH. Kidney International Reports, 2017, 2, 1111-1121.	0.4	8
188	Clâ^' and H+ coupling properties and subcellular localizations of wildtype and disease-associated variants of the voltage-gated Clâ^'/H+ exchanger ClC-5. Journal of Biological Chemistry, 2020, 295, 1464-1473.	1.6	8
189	High Prevalence of Kidney Cysts in Patients With CYP24A1 Deficiency. Kidney International Reports, 2021, 6, 1895-1903.	0.4	8
190	Subsequent urinary stone events are predicted by the magnitude of urinary oxalate excretion in enteric hyperoxaluria. Nephrology Dialysis Transplantation, 2021, 36, 2208-2215.	0.4	8
191	Genotype Phenotype Correlation in Dent Disease 2 and Review of the Literature: OCRL Gene Pleiotropism or Extreme Phenotypic Variability of Lowe Syndrome?. Genes, 2021, 12, 1597.	1.0	8
192	Kidney Cysts in Hypophosphatemic Rickets With Hypercalciuria: A Case Series. Kidney Medicine, 2022, 4, 100419.	1.0	8
193	Randomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria. , 2022, 1, .		8
194	Genetic Causes of Kidney Stones and Kidney Failure. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 2-18.	1.3	7
195	Association of urinary citrate excretion, pH, and net gastrointestinal alkali absorption with diet, diuretic use, and blood glucose concentration. Physiological Reports, 2017, 5, e13411.	0.7	7
196	Antiurolithic activity and biotransformation of galloylquinic acids by Aspergillus alliaceus ATCC10060, Aspergillus brasiliensis ATCC 16404, and Cunninghamella elegans ATCC 10028b. Biocatalysis and Agricultural Biotechnology, 2019, 18, 101012.	1.5	7
197	Nephrotoxin Exposure in the 3 Years following Hospital Discharge Predicts Development or Worsening of Chronic Kidney Disease among Acute Kidney Injury Survivors. American Journal of Nephrology, 2022, 53, 273-281.	1.4	7
198	The association of matrix Gla protein isomers with calcification in capsules surrounding silicone breast implants. Biomaterials, 2011, 32, 8364-8373.	5.7	6

#	Article	IF	Citations
199	Characterization of Inner Medullary Collecting Duct Plug Formation Among Idiopathic Calcium Oxalate Stone Formers. Urology, 2016, 94, 47-52.	0.5	6
200	Non-steroidal anti-inflammatory drugs for renal colic. Lancet, The, 2016, 387, 1971-1972.	6.3	6
201	Genome-wide Association Study of 24-Hour Urinary Excretion of Calcium, Magnesium, and Uric Acid. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 448-460.	1.2	6
202	Automatic detection of calcium phosphate deposit plugs at the terminal ends of kidney tubules. Healthcare Technology Letters, 2019, 6, 271-274.	1.9	6
203	Automated radiomic analysis of CT images to predict likelihood of spontaneous passage of symptomatic renal stones. Emergency Radiology, 2021, 28, 781-788.	1.0	6
204	Natural History of Clinical, Laboratory, and Echocardiographic Parameters of a Primary Hyperoxaluria Cohort on Long Term Hemodialysis. Frontiers in Medicine, 2021, 8, 592357.	1.2	6
205	Sex Steroid Hormone Levels May Not Explain Gender Differences in Development of Nephrolithiasis. Journal of Endourology, 2015, 29, 1341-1345.	1.1	5
206	Fecal electrolyte testing for evaluation of unexplained diarrhea: Validation of body fluid test accuracy in the absence of a reference method. Clinical Biochemistry, 2015, 48, 1126-1130.	0.8	5
207	Bariatric Surgery and Kidney Health. Journal of the American Society of Nephrology: JASN, 2018, 29, 1085-1086.	3.0	5
208	Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	5
209	Clinician perspectives on inpatient cystatin C utilization: A qualitative case study at Mayo Clinic. PLoS ONE, 2020, 15, e0243618.	1.1	5
210	Uncovering a Novel Stone in 27 Patients: Calcium Tartrate Tetrahydrate. Urology, 2019, 126, 49-53.	0.5	4
211	Genome-Wide Association Meta-Analysis of Individuals of European Ancestry Identifies Suggestive Loci for Sodium Intake, Potassium Intake, and Their Ratio Measured from 24-Hour or Half-Day Urine Samples. Journal of Nutrition, 2020, 150, 2635-2645.	1.3	4
212	Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria. BMC Nephrology, 2020, 21, 133.	0.8	4
213	Invited response to recurrence of oxalate nephropathy after isolated kidney transplantation for primary hyperoxaluria type 2. American Journal of Transplantation, 2018, 18, 527.	2.6	4
214	Clinical Outcomes and Histological Patterns in Oxalate Nephropathy due to Enteric and Nonenteric Risk Factors. American Journal of Nephrology, 2021, 52, 961-968.	1.4	4
215	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology, 2021, 36, 2747-2757.	0.9	3
216	Inflammatory Cells in Nephrectomy Tissue from Patients without and with a History of Urinary Stone Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 414-422.	2.2	3

#	Article	IF	CITATIONS
217	A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate. Kidney International Reports, 2022, 7, 1690-1693.	0.4	3
218	Inching toward a Greater Understanding of Genetic Hypercalciuria. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1460-1462.	2.2	2
219	Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: Incidence, risk factors, and effect on renal allograft function. American Journal of Transplantation, 2021, , .	2.6	2
220	1H Nuclear Magnetic Resonance Spectroscopy-Based Methods for the Quantification of Proteins in Urine. Analytical Chemistry, 2021, 93, 13177-13186.	3.2	2
221	Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1. American Journal of Kidney Diseases, 2022, 80, 373-382.	2.1	2
222	Medical Management. Clinical Reviews in Bone and Mineral Metabolism, 2004, 2, 237-252.	1.3	1
223	Isolation, Propagation, and Analysis of Biological Nanoparticles. Methods in Molecular Biology, 2011, 790, 263-275.	0.4	1
224	Infection-Related Kidney Stones. Clinical Reviews in Bone and Mineral Metabolism, 2011, 9, 218-228.	1.3	1
225	Eosinophiluria is common among patients after ileal conduit surgery. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1869-71.	1.4	1
226	Diagnostic Imaging for Kidney Stones—Reply. JAMA - Journal of the American Medical Association, 2020, 324, 1465.	3.8	1
227	CYP24A1 deficiency causing persistent hypercalciuria in a stone former. Journal of Nephrology, 2021, 34, 949-951.	0.9	1
228	Surgical interventions for symptomatic urinary stones during pregnancy. Chinese Medical Journal, 2021, 134, 1994-1996.	0.9	1
229	Microsporidium Infection–Associated Acute Kidney Injury in a Patient With HIV. Kidney Medicine, 2021, 4, 100390.	1.0	1
230	Commentary. Clinical Chemistry, 2013, 59, 890-890.	1.5	0
231	Commentary. Clinical Chemistry, 2016, 62, 440-440.	1.5	0
232	Editorial Comment. Journal of Urology, 2016, 196, 1147-1148.	0.2	0
233	Editorial Comment. Journal of Urology, 2017, 197, 409-410.	0.2	0
234	The first Sri Lankan family with Dent disease-1 due to a pathogenic variant in the CLCN5 gene: a case report. BMC Research Notes, 2017, 10, 539.	0.6	0

#	Article	IF	CITATIONS
235	The Case An unusual cause of tender skin lesion in an end-stage kidney disease patient. Kidney International, 2021, 99, 275-276.	2.6	0
236	Has Noninvasive Kidney Transplant Surveillance Finally Arrived?. Clinical Chemistry, 2021, 67, 1047-1049.	1.5	0
237	MO047STABLE EGFR IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 TREATED WITH LUMASIRAN, REGARDLESS OF KIDNEY FUNCTION AT START OF TREATMENT. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	O
238	FC 013LUMASIRAN DEMONSTRATED COMPARABLE OXALATE REDUCTION AND SAFETY IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
239	End Points for Clinical Trials in Hyperoxaluria: Case Study of Patient-Focused Drug Development in a Rare Disease. American Journal of Kidney Diseases, 2021, , .	2.1	0
240	Spectromicroscopy of microbial signatures within human calcifications. FASEB Journal, 2006, 20, A101.	0.2	0
241	Biofilm formation by biologic nanoparticles may require extracellular RNA and intact ribosomal function. FASEB Journal, 2009, 23, 817.8.	0.2	O
242	Biologic Nanoparticles Calcify and Form Bacteriaâ€like Biofilm In Vitro. FASEB Journal, 2009, 23, 593.14.	0.2	0
243	Comparison of clinical features of pregnant and non-pregnant females with primary hyperoxaluria. Journal of Nephrology, 2022, , 1.	0.9	O
244	New Insights Regarding Organ Transplantation in Primary Hyperoxaluria Type 1. Kidney International Reports, 2022, 7, 146-148.	0.4	0
245	FC070: Lumasiran for Patients with Primary Hyperoxaluria Type 1 with Impaired Kidney Function: Data from the 6-Month Analysis of the Phase 3 Illuminate-C Trial. Nephrology Dialysis Transplantation, 2022, 37 , .	0.4	0